Mark Harries

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Paul Ellis, Nazneen Rahman, Alexander Gutin, 2018, Nature Medicine.

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.

Vicky Goh, Mariyah Selmi, Balaji Ganeshan, 2014, Radiology.